Dermomina® clay achieves high closure rates in non-infected diabetic foot ulcers
Summary: February 11, 2026 pre-experimental observational study (Dominican Republic, March 2022–October 2024) assesses topical Dermomina clay (aluminosilicate) as adjunct in 24 Wagner grade 1-3 DFUs (14 non-infected, 10 infected). Non-infected ulcers showed faster healing (92.9% complete closure by week 20 vs. 40% infected; weekly reduction 12.2% vs. 6.5%; p<0.001). Median closure time shorter in non-infected; factors delaying healing: infection, HbA1c >7%, age >60, size >20 cm², higher Wagner, PAD. Mild/transient AEs (8.3%); no discontinuations/amputations. Supports clay as accessible adjunct for non-infected DFUs; calls for controlled trials to confirm role in evidence-based care.
Key Highlights:
- Outcomes: High closure in non-infected; infection major barrier.
- Safety: Favorable profile; low-cost potential.
- Relevance: Natural adjunct for early-stage DFUs in resource-limited settings.
Keywords: Dermomina clay, non-infected DFU, closure rate, adjunctive therapy